Health
Health
ding Awareness and Education 301. Expanding medicare annual wellness benefit to include kidney disease screening subsection id="H4EE87D1205C44BC3B21E142450
HR 6214 - 119Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sectors are deterministic matches from official Congress.gov data and cached bill text. They are source-derived signals, not conclusions about intent or economic effect.
Evidence matches count official fields, normalized subjects, cached text snippets, or extracted entities that matched the sector rules.
Impact is a bill-level rollup used for sorting and filtering. It is not an economic impact estimate.
Confidence is the strongest individual match score behind that sector.
Evidence snippets show why a sector matched and can repeat when Congress.gov repeats the same phrase across official fields.
Health
Health
ding Awareness and Education 301. Expanding medicare annual wellness benefit to include kidney disease screening subsection id="H4EE87D1205C44BC3B21E142450
le id="HBDC4968227E648F794BA43F162C5E42B" III Preventing Kidney Disease and Expanding Awareness and Education 301. Expanding medicare annual wel
-entry idref="HBF6FA5B2A37A4D33B3CA11463188E59C" level="section" Sec. 302. Increasing access to medicare kidney disease education benefit. en
n 302. Increasing access to medicare kidney disease education benefit (a) In general
Energy and Commerce Committee Standing House
jurisdiction addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _________
Kidney Care Access Protection Act Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provis
ceeding years shall take into account the forecast error from the most recently available year for which there is final data. The forecast error adjustment under this subclause shall apply whenever the difference between the forecasted and
Official Congressional Budget Office cost estimate links associated with this bill through Congress.gov records.
CBO estimates are official source documents with their own assumptions, scope, and publication dates. They can score a bill, a version of a bill, or a broader legislative package.
LawLinter stores the source link from Congress.gov and does not replace the CBO document. Use these cards as pointers for source review, not as independent fiscal advice.
CBO context shows source-attributed Congressional Budget Office cost estimates linked from official Congress.gov bill records. It is research context only; read the official CBO source document for assumptions, scope, and dates.
Official USAspending.gov award records for agencies connected through bill-text agency signals. This helps show the existing agency spending landscape around the bill, not spending caused by the bill.
USAspending records describe federal awards, grants, contracts, loans, direct payments, recipients, agencies, and dates reported through the official public spending system.
LawLinter links this context through agency names detected in bill text. That bridge is a research shortcut and should not be read as a legal or budget conclusion.
USAspending context shows official public award records for agencies connected through LawLinter bill-text agency signals. It is historical spending and award context only, not proof that this bill caused, authorized, required, or changed any award, grant, contract, payment, or program spending.
MEDICAID ENTITLEMENT FOR 30 - FY 2026 - T19
MEDICAID ENTITLEMENT FOR 30 - FY 2025 - T19
MEDICAID ENTITLEMENT FOR 30 - FY 2024 - T19
MEDICAID ENTITLEMENT FOR 30 - FY 2026 - T19
MEDICAID ENTITLEMENT FOR 30 - FY 2023 - T19
CSC6-2021
MEDICAID ENTITLEMENT FOR 34 - FY 2023 - T19
MEDICAID ENTITLEMENT FOR 34 - FY 2026 - T19
MEDICAID ENTITLEMENT FOR 34 - FY 2023 - T19
MEDICAID ENTITLEMENT FOR 34 - FY 2025 - T19
CK19-1904 EPIDEMIOLOGY AND LABORATORY CAPACITY FOR PREVENTION AND CONTROL OF EMERGING INFECTIOUS DISEASES (ELC)
CSC6-2021
Related FEC/OpenFEC campaign-finance records for lawmakers and candidates tied to this bill through source-attributed legislative relationships. These are not donations to the bill itself.
Amounts shown here are campaign-finance totals for sponsor or cosponsor-linked candidates and their committees in the displayed FEC cycle.
They are not donations to this bill, spending on this bill, or proof that money influenced or caused sponsorship, cosponsorship, votes, or legislative outcomes.
If multiple linked lawmakers have FEC records, this section can show multiple candidate cards and separate sponsor/cosponsor rollups.
Campaign-finance context uses source-attributed FEC/OpenFEC records that are related or relevant to the displayed bill, lawmaker, candidate, committee, or legislative relationship through deterministic links. It is research context only, not proof of influence, causation, endorsement, or that money caused a sponsorship, vote, or legislative outcome.
Related LDA.gov filings where public lobbying activity descriptions reference this bill. These records are source-attributed research context, not evidence of influence or causation.
LDA filings are public lobbying disclosure records. LawLinter links them here only when the filing activity text contains an exact-looking reference to this bill.
A filing can mention many issues, clients, agencies, or bills. A match should be treated as a pointer for review, not as a conclusion about why legislation changed or how any lawmaker acted.
Lobbying context uses source-attributed LDA.gov records that appear related to this bill through bill references in public lobbying activity descriptions. It is research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.
Health policy related to kidney, renal, and dialysis care. Including, Medicare reimbursement, coverage, and policies pursuant to the Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS); bundling of certain oral-only drugs to the ESRD PPS; support for innovative therapies for patients living with kidney disease. KCC supports the Kidney Care Access Protection Act (HR 6214, S 2730) which addresses some of these issues. Medicare Secondary Payer issues to protect patient choice of coverage for individuals with ESRD, including support for the Restore Protections for Dialysis Patients Act (HR 2199, S.1173.). Introduction to Kidney Care Council as an organization, our member companies, and the patients they serve.
Health policy related to kidney, renal, and dialysis care. Including, Medicare reimbursement, coverage, and policies pursuant to the Medicare End Stage Renal Disease (ESRD) Prospective Payment System (PPS); bundling of certain oral-only drugs to the ESRD PPS; support for innovative therapies for patients living with kidney disease. KCC supports the Kidney Care Access Protection Act (HR 6214, S 2730) which addresses some of these issues. Medicare Secondary Payer issues to protect patient choice of coverage for individuals with ESRD, including support for the Restore Protections for Dialysis Patients Act (HR 2199, S.1173.). Introduction to Kidney Care Council as an organization, our member companies, and the patients they serve.
![Rep. Miller, Carol D. [R-WV-1]](https://www.congress.gov/img/member/m001205_200.jpg)
![Rep. Sewell, Terri A. [D-AL-7]](https://www.congress.gov/img/member/s001185_200.jpg)
![Rep. Clarke, Yvette D. [D-NY-9]](https://www.congress.gov/img/member/674dfc6b5c48ff736e6e1762_200.jpg)
![Rep. Rulli, Michael A. [R-OH-6]](https://www.congress.gov/img/member/69401dcc8cd6e06e9e3b36de_200.jpg)
![Rep. Tenney, Claudia [R-NY-24]](https://www.congress.gov/img/member/t000478_200.jpg)
![Rep. Kelly, Mike [R-PA-16]](https://www.congress.gov/img/member/k000376_200.jpg)
![Rep. Carter, Troy A. [D-LA-2]](https://www.congress.gov/img/member/c001125_200.jpg)
![Rep. Murphy, Gregory F. [R-NC-3]](https://www.congress.gov/img/member/m001210_200.jpg)
![Rep. Davis, Donald G. [D-NC-1]](https://www.congress.gov/img/member/d000230_200.jpg)
![Rep. Fitzpatrick, Brian K. [R-PA-1]](https://www.congress.gov/img/member/116_rp_pa_1_fitzpatrick_brian_200.jpg)
![Rep. Wilson, Joe [R-SC-2]](https://www.congress.gov/img/member/116_rp_sc_2_wilson_joe_200.jpg)
![Rep. Panetta, Jimmy [D-CA-19]](https://www.congress.gov/img/member/116_rp_ca_20_panetta_jimmy_200.jpg)
![Rep. Langworthy, Nicholas A. [R-NY-23]](https://www.congress.gov/img/member/680901e76c2e6631263de716_200.jpg)
![Rep. Moore, Blake D. [R-UT-1]](https://www.congress.gov/img/member/m001213_200.jpg)
Introduced in House
Introduced in House
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.